Table A1:
Applicability of Studies Given Full-Text Review
| Objective: To Assess the Cost-Effectiveness of the LAAC Device | |||||
|---|---|---|---|---|---|
| Author, Year | Is the study population similar to the question? | Are the interventions similar to the question? | Is the health care system in which the study was conducted sufficiently similar to the current Ontario context? | Was/were the perspective(s) clearly stated, and what were they? | Are estimates of relative treatment effect from the best available sources? |
| Patients Without Contraindications to OACs | |||||
| Amorosi et al, 201539 | Yes (assumption) | Yes, but some absent (LAAC device vs. dabigatran vs. warfarin) | No (Germany) | Yes (public health care payer) | No, new evidence available (PREVAIL) |
| Freeman et al, 201634 | Yes | Yes, but some absent (LAAC device vs. dabigatran vs. warfarin) | No (U.S.) | Yes (public health care payer) | Yes |
| Lee et al, 201635 | Yes | Yes (LAAC device vs. aspirin vs. aspirin + clopidogrel vs. apixaban vs. dabigatran vs. rivaroxaban vs. warfarin) | No (U.S.) | Yes (public health care payer) | Yes |
| Micieli et al, 201637 | Yes | Yes (LAAC device vs. apixaban vs. dabigatran vs. rivaroxaban vs. warfarin) | Yes (Ontario) | Yes (public health care payer) | No, new evidence available (PREVAIL) |
| Reddy et al, 201533 | Yes | Yes, but some absent (LAAC device vs. dabigatran vs. warfarin) | No (U.S.) | Yes (public health care payer) | No, new evidence available (PREVAIL) |
| Singh et al, 201338 | Yes | Yes, but some absent (LAAC device vs. dabigatran vs. warfarin) | Yes (Ontario) | Yes (public health care payer) | No, new evidence available (PREVAIL) |
| Patients With Contraindications to OACs | |||||
| Reddy et al, 201632 | Yes | Yes (LAAC device vs. aspirin vs. apixaban) | No (Germany) | Yes (public health care payer) | Yes |
| Saw et al, 201636 | Yes | Yes (LAAC vs. aspirin) | Yes (Ontario) | Yes (public health care payer) | No, new evidence available (ASAP) |
| Author, Year | Are all future costs and outcomes discounted? (If yes, at what rate?) | Is the value of health effects expressed in terms of quality-adjusted life-years? | Are costs and outcomes from other sectors fully and appropriately measured and valued? | Overall judgment (directly applicable/partially applicable/not applicable) |
|---|---|---|---|---|
| Patients Without Contraindications to OACs | ||||
| Amorosi et al, 201539 | No | No | No | Partially applicable |
| Freeman et al, 201634 | Yes (3%) | Yes | No | Partially applicable |
| Lee et al, 201635 | Yes (3%) | Yes | No | Partially applicable |
| Micieli et al, 201637 | Yes (5%) | Yes | No | Directly applicable |
| Reddy et al, 201533 | Yes (3%) | Yes | No | Partially applicable |
| Singh et al, 201338 | Yes (5%) | Yes | No | Partially applicable |
| Patients With Contraindications to OACs | ||||
| Reddy et al, 201632 | Yes (3%) | Yes | No | Partially applicable |
| Saw et al, 201636 | No (5%) | Yes | No | Directly applicable |
Abbreviations: LAAC device, left atrial appendage closure device with delivery system; OAC, oral anticoagulant.